We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
26
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$60.8M 0.39%
1,787,807
– –
INSM icon
27
Insmed
INSM
$22.4B
$60.4M 0.39%
2,077,601
+225,619
+12% +$5.85M
KOD icon
28
Kodiak Sciences
KOD
$2.5B
$59.7M 0.38%
9,145,115
– –
KNSA icon
29
Kiniksa Pharmaceuticals
KNSA
$6.23B
$54.2M 0.35%
3,000,000
– –
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$52.8M 0.34%
1,016,306
+701,063
+222% +$32.3M
DBVT
31
DBV Technologies
DBVT
$813M
$42.5M 0.27%
550,956
– –
QURE icon
32
uniQure
QURE
$2.75B
$36.1M 0.23%
605,000
– –
NGNE icon
33
Neurogene
NGNE
$672M
$29.5M 0.19%
546,708
– –
ZYME icon
34
Zymeworks
ZYME
$1.62B
$27.6M 0.18%
1,708,472
– –
KRYS icon
35
Krystal Biotech
KRYS
$10.7B
$25.8M 0.17%
784,674
– –
RARX
36
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$18.4M 0.12%
823,113
– –
MRUS
37
DELISTED
Merus
MRUS
$17.1M 0.11%
1,160,014
– –
AXSM icon
38
Axsome Therapeutics
AXSM
$11.7B
$17.1M 0.11%
+1,200,000
New +$11.1M
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
$15.1M 0.1%
673,908
– –
CPRX
40
DELISTED
Catalyst Pharmaceutical
CPRX
$14.8M 0.09%
2,900,000
– –
SYRE icon
41
Spyre Therapeutics
SYRE
$8.5B
$13.8M 0.09%
68,544
– –
XNCR icon
42
Xencor
XNCR
$1.45B
$13.3M 0.09%
428,120
-12,066
-3% -$401K
ACGN
43
DELISTED
Aceragen Inc
ACGN
$12.3M 0.08%
284,984
+215
+0.1% +$10.4K
DERM
44
DELISTED
Dermira, Inc.
DERM
$12.3M 0.08%
+906,943
New +$7.56M
MRKR icon
45
Marker Therapeutics
MRKR
$18.5M
$9.9M 0.06%
150,000
– –
SGMO
46
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.54M 0.06%
999,823
– –
ABEO icon
47
Abeona Therapeutics
ABEO
$355M
$9.48M 0.06%
51,529
-32,598
-39% -$5.83M
BLCM
48
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9.02M 0.06%
267,782
– –
ANAB icon
49
AnaptysBio
ANAB
$1.54B
$8.26M 0.05%
113,086
– –
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$8.05M 0.05%
250,000
– –
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Baker Bros. Advisors held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Baker Bros. Advisors's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Baker Bros. Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Baker Bros. Advisors opened 7 new positions and closed 4 in Q1 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.